CHEMOSAT® is an innovative treatment for liver cancer.
The Delcath Hepatic CHEMOSAT® Delivery System is used for percutaneous intra-arterial administration of chemotherapeutic agent (melphalan hydrochloride) to the liver with subsequent extracorporeal filtration of the regional (hepatic) venous blood, lowering the concentration of chemotherapeutic agent in the blood before returning it to the systemic venous circulation.
CHEMOSAT® is licenced throughout the European Union but is currently not reimbursed in Spain and is available on a self pay basis only. Some premium insurance plans may contribute the cost, please consult with your insurer.
Please contact us if you wish to know more or would like to discuss introducing this treatment at your hospital.